C WorldWide Group Holding A S Boosts Stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

C WorldWide Group Holding A S lifted its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 35.6% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 190,329 shares of the biotechnology company’s stock after purchasing an additional 50,000 shares during the period. C WorldWide Group Holding A S owned 0.20% of Sarepta Therapeutics worth $23,142,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of SRPT. Blue Trust Inc. increased its stake in shares of Sarepta Therapeutics by 896.5% in the 3rd quarter. Blue Trust Inc. now owns 568 shares of the biotechnology company’s stock worth $71,000 after purchasing an additional 511 shares in the last quarter. International Assets Investment Management LLC increased its stake in shares of Sarepta Therapeutics by 59,222.7% in the 3rd quarter. International Assets Investment Management LLC now owns 75,933 shares of the biotechnology company’s stock worth $9,483,000 after purchasing an additional 75,805 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Sarepta Therapeutics by 112.7% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,002 shares of the biotechnology company’s stock worth $747,000 after purchasing an additional 3,180 shares in the last quarter. State of Alaska Department of Revenue increased its stake in shares of Sarepta Therapeutics by 7.3% in the 3rd quarter. State of Alaska Department of Revenue now owns 11,035 shares of the biotechnology company’s stock worth $1,378,000 after purchasing an additional 750 shares in the last quarter. Finally, Riggs Asset Managment Co. Inc. increased its stake in shares of Sarepta Therapeutics by 666.7% in the 3rd quarter. Riggs Asset Managment Co. Inc. now owns 2,300 shares of the biotechnology company’s stock worth $287,000 after purchasing an additional 2,000 shares in the last quarter. 86.68% of the stock is currently owned by hedge funds and other institutional investors.

Sarepta Therapeutics Stock Down 2.0 %

Shares of NASDAQ:SRPT opened at $106.28 on Monday. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. Sarepta Therapeutics, Inc. has a 12 month low of $101.15 and a 12 month high of $173.25. The company has a 50-day moving average price of $117.54 and a 200 day moving average price of $123.36. The company has a market cap of $10.15 billion, a price-to-earnings ratio of 85.02 and a beta of 0.75.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on SRPT shares. Cantor Fitzgerald upgraded Sarepta Therapeutics from a “neutral” rating to an “overweight” rating and upped their price objective for the stock from $152.00 to $167.00 in a research note on Thursday, November 7th. Robert W. Baird cut their price target on Sarepta Therapeutics from $200.00 to $193.00 and set an “outperform” rating for the company in a research note on Thursday, November 7th. HC Wainwright reiterated a “sell” rating and issued a $75.00 price target on shares of Sarepta Therapeutics in a research note on Thursday, February 13th. Piper Sandler cut their price target on Sarepta Therapeutics from $200.00 to $182.00 and set an “overweight” rating for the company in a research note on Wednesday, November 27th. Finally, Guggenheim increased their price target on Sarepta Therapeutics from $148.00 to $150.00 and gave the stock a “buy” rating in a research note on Thursday, November 7th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $176.77.

Insider Activity at Sarepta Therapeutics

In related news, Director Kathryn Jean Boor sold 1,636 shares of the stock in a transaction dated Thursday, December 5th. The shares were sold at an average price of $125.55, for a total value of $205,399.80. Following the completion of the transaction, the director now owns 5,880 shares of the company’s stock, valued at approximately $738,234. This trade represents a 21.77 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the firm’s stock in a transaction dated Thursday, December 12th. The stock was sold at an average price of $124.84, for a total transaction of $1,310,820.00. Following the completion of the sale, the director now directly owns 22,840 shares of the company’s stock, valued at approximately $2,851,345.60. The trade was a 31.49 % decrease in their position. The disclosure for this sale can be found here. 7.70% of the stock is owned by insiders.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.